

March 28, 2011
Mumbai

CRISIL Research assigns IPO grade '1/5' to Aanjaneya Lifecare Ltd

CRISIL has assigned a CRISIL IPO Grade "1/5" (pronounced "one on five") to the proposed initial public offer (IPO) of Aanjaneya Lifecare Ltd (Aanjaneya). This grade indicates that the fundamentals of the IPO are 'poor' relative to the other listed equity securities in India. However, this grade is not an opinion on whether the issue price is appropriate in relation to the issue fundamentals. The grade is not a recommendation to buy, sell or hold the graded instrument, or a comment on the graded instrument's future market price or its suitability for a particular investor.

The assigned grade reflects the company's limited corporate governance practices. In Aug 2009, Aanjaneya was acquired by Finaventure Capital (FCL), a shell company listed on the Bombay Stock Exchange (BSE), through a share swap, whereby Aanjaneya's promoters parted 33.75% holding to FCL's shareholders. For the transaction, Aanjaneya was valued at Rs 280 mn and the implied valuation of FCL was Rs 143 mn. CRISIL Equities believes that the amount paid does not correspond with the business prospects of FCL. In addition, the independent directors' engagement and board practices needs to be strengthened.

Aanjaneya's focus areas – formulations for cough and cold, anti-malarial, anti-cancer and herbal medicine segments – are expected to see steady demand growth. The company, an anti-malarial API manufacturer, entered into codeine-based formulation by acquiring Prophyla Biologicals Private Ltd in March 2010. Prophyla was into formulation job-work for large Indian pharmaceutical companies and had one of the largest codeine quotas in the country. Aanjaneya's key strength is its ability to source quinine and codeine, which are the two key raw materials for anti-malarial and cough and cold formulations. As formulations for anti-malaria and cough syrup are in constant demand, Aanjaneya's unique position aids in revenue stability. All the clients are dependent on Aanjaneya for the APIs and formulations. The company has strong relationships with clients like Cipla, Wockhardt, Tablets India, Zydus Cadilla and others.

Aanjaneya has entered the branded segment with its own codeine-based formulations and lozenges for cough and cold. Post IPO, the company plans to focus on anti-cancer and own brands. The codeine business is highly regulated by the Bureau of Narcotics (BoN). BoN controls the quota of codeine and constantly monitors for misuse of codeine. As codeine can only be purchased from BoN, any production shortfall or non-import by BoN can limit the company's growth potential.

About the company and the issue

The company was incorporated in 2006, but it commenced commercial production of APIs (active pharmaceuticals ingredients) of quinine salts (a second generation anti malarial), in 2007. In 2010, the company ventured into manufacturing of finished dosage forms by acquiring the assets of Prophyla Biologicals Pvt. Ltd through an asset purchase agreement dated March 30, 2010 and deed of assignment for trademarks dated April 1, 2010.

In 2009-10, the company reported turnover of Rs 1617 mn and net profit of Rs 151 mn. Aanjaneya's RoE for the year was 48.7%.

Through the IPO, Aanjaneya plans to issue 5 mn new shares and has outlined a capex of Rs 1000 mn through the IPO proceeds. The proceeds will be utilized to set up an anti-cancer facility, an API block in Mahad, expansion of its R&D facility, setting up of quality assurance facility and product development facility and for branding and registration of its products in the international markets

About CRISIL IPO Grading

CRISIL IPO (Initial Public Offering) grading is an opinion on the fundamentals of the graded issue that reflects CRISIL's independence and expertise. This opinion is expressed as a relative assessment in relation to other listed equity securities in India. The assessment is based on a grading exercise carried out by industry specialists from CRISIL Research. A CRISIL IPO Grade 5/5 indicates strong fundamentals and a CRISIL IPO Grade 1/5 indicates poor fundamentals. CRISIL IPO Grading reflects its assessment of the graded company's equity fundamentals as distinct from an assessment of debt fundamentals. A CRISIL IPO Grade should not be construed to mean a comment on the price of the graded security nor is it a recommendation to invest or not to invest in the graded security.

Media Contacts	Analytical Contacts
<p>Mitu Samar Head, Market Development & Communications CRISIL Limited Tel: +91-22- 3342 1838 Mobile: +91- 98200 61934 Fax: +91-22- 3342 3001 E-mail: msamar@crisil.com</p> <p>Tanuja Abhinandan Market Development & Communications CRISIL Limited Phone: +91-22- 3342 1818 Mobile: +91- 98192 48980 Fax: +91-22- 3342 3001 Email: tabhinandan@crisil.com</p>	<p>Tarun Bhatia Director, Capital Markets CRISIL Research Tel: +91-22- 3342 3226 E-mail: tbatia@crisil.com</p> <p>Chetan Majithia Head, Equities CRISIL Research Tel: +91-22- 3342 4148 E-mail: chetanmajithia@crisil.com</p>

About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

About CRISIL Research

CRISIL Research is India's largest independent, integrated research house. We leverage our unique, integrated research platform and capabilities spanning the entire economy-industry company spectrum to deliver superior perspectives and insights to over 750 domestic and global clients, through a range of subscription products and customised solutions.

CRISIL PRIVACY NOTICE

Contacting us via e-mail or registering with CRISIL reveals your e-mail address and any other information you include such as phone number and/or mailing address. We will use this information to help us process your registration, fulfill your request or respond to your inquiry. All of your personal information will be stored in a secure database in India. Access to this database is limited to authorized persons.

Occasionally, we use data collected about customers and prospects to inform them about products or services from CRISIL, and our parent company Standard & Poor's (a subsidiary of The McGraw-Hill Companies), and reputable outside companies that may be of interest to them. Many of our customers find these e-mail promotions valuable, whether they are shopping for merchandise, taking advantage of a special offer, or purchasing unique services. On rare occasions, and subject to applicable laws, CRISIL may also share your information with outside "3rd Party" vendors who will be authorized to use this information solely to perform services (such as a "mailing" house) on our behalf.

If at any time you would like your name removed from lists that are shared for promotional reasons within CRISIL, Standard & Poor's, and with other units of The McGraw-Hill Companies, or with third parties simply send a written request to privacy@crisil.com or Privacy Official, CRISIL House, Central Avenue, Hiranandani Business Park, Powai, Mumbai - 400 076, India.

You can also send an email request to privacy@crisil.com if you would like to confirm the accuracy of the information we have collected from you, or if you have questions about the uses of this information.

For more information about The McGraw-Hill Companies Privacy Policy, please visit www.mcgrawhill.com/privacy.html

Last updated: 01 January, 2010

Disclaimer

A CRISIL IPO Grading is a one-time assessment and reflects CRISIL's current opinion on the fundamentals of the graded equity issue in relation to other listed equity securities in India. A CRISIL IPO Grading is neither an audit of the issuer by CRISIL nor is it a credit rating. Every CRISIL IPO Grading is based on the information provided by the issuer or obtained by CRISIL from sources it considers reliable. CRISIL does not guarantee the completeness or accuracy of the information on which the grading is based. A CRISIL IPO Grading is not a recommendation to buy / sell or hold the graded instrument; it does not comment on the issue price, future market price or suitability for a particular investor.

CRISIL is not responsible for any errors and especially states that it has no financial liability whatsoever to the subscribers / users / transmitters / distributors of CRISIL IPO Gradings. For information on any IPO grading assigned by CRISIL, please contact 'Client Servicing' at +91-22-33423561, or via e-mail: clientservicing@crisil.com.

For more information on CRISIL IPO Gradings, please visit <http://www.crisil.com/ipo-gradings>

This press release is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The Press release may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution of its Press Releases for consideration or otherwise through any media including websites, portals etc.